healing without harm
PURPOSE
We engineer tumor-responsive drug delivery systems that activate chemotherapy precisely where it is needed, reducing harm to healthy tissue to extend meaningful survival for patients with cancer.
MATH-01
Our initial target indication for our lead drug is second-line pancreatic cancer, with potential expansion into colorectal and other cancers.